ImmuPharma Strengthens Position with Progress on P140 Platform and Global Collaborations

PUBLISHED: 19 May 2025 @ 17:57 | Comments (0) | More info about Fiona Craig

ImmuPharma PLC (LSE:IMM) has released its financial results for 2024, showcasing meaningful progress in the development of its innovative P140 platform for autoimmune diseases. The company managed to reduce its financial losses for the year and successfully secured additional funding, bolstering its operational runway.

A highlight of the year was the advancement of preclinical research around the P140 platform, revealing new insights into its diagnostic potential and its ability to monitor treatment effectiveness in autoimmune conditions. Notably, studies further confirmed P140’s distinctive mechanism of action—delivering therapeutic effects without suppressing the immune system. This differentiator enhances the platform’s appeal and adds value to ImmuPharma’s growing intellectual property assets.

These scientific breakthroughs have sparked interest from potential international partners, with discussions underway that could lead to strategic commercial agreements. The company is now well-positioned to expand its global footprint and play a leading role in reshaping treatment options for autoimmune diseases.

About ImmuPharma PLC

ImmuPharma is a UK-based biopharmaceutical company specializing in the discovery and development of novel therapies for autoimmune disorders. Its flagship technology, P140, is designed to restore immune system balance and offers a new approach to treating conditions such as systemic lupus erythematosus (SLE).

Average Daily Trading Volume: 3,086,600
Technical Sentiment: Buy
Market Capitalization: £16.77 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.